Motley Fool Money - Microsoft’s Big Deal and Coinbase’s Big Debut

Episode Date: April 16, 2021

Microsoft buys Nuance Communications in a $16 billion deal. Coinbase makes an $86 billion Wall Street debut. FDA hits the pause button on Johnson & Johnson’s COVID-19 vaccine. Katrina Lake steps down as the CEO of Stitch Fix. Bed Bath & Beyond slips on earnings. White Claw introduces Surge. Pepsi serves up big growth in its snack division. And IBM unveils a surprising name for its cloud business. Motley Fool analysts Emily Flippen and Ron Gross discuss those stories and share two stocks on their radar: Bilibili and Ecolab. Plus, e.l.f. Beauty CFO Mandy Fields talks about the big business of cosmetics. Looking for more stocks for your radar? Get 50% off Stock Advisor by going to http://RadarStocks.fool.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

If you're a small business owner, you already know what it takes to keep everything moving. You're juggling customers, invoices, and about 100 decisions every day. Thankfully, taxes don't have to be one more thing on that list. With Intuit TurboTax, you can get your business taxes done for you with a full service expert. TurboTax matches you with your dedicated tax expert. Who knows your industry understands your business write-offs and gives you the personalized advice your business deserves. upload your documents right in the app, hand everything off, and still feel like you're in the loop the whole way through.

You can even get real-time updates on your expert's progress right in the app, which makes it so much easier to stay on track. And you can get unlimited expert help at no extra cost, even on nights and weekends during tax season. Visit turbotax.com to get matched with an expert today, only available with TurboTax full service experts. Everybody needs money. That's why they call it money. From Fool Global Headquarters, this is Motley Fool Money Radio Show. I'm Chris Hill, joining me this week's senior analyst, Emily Flippin, and Ron Gross. Good to see you both. How you doing, Chris? Hey, Chris. We've got the latest headlines from Wall Street. We will dig into the big business of beauty and cosmetics.

And as always, we've got a couple of stocks on our radar. But we begin with a big deal in big tech. Microsoft announced it's buying Nuance Communications, a voice recognition company, in a deal worth $16 billion. CEO Satya Nadella says they will use the technology in their healthcare cloud products. This makes Nuisance the second largest acquisition Microsoft has ever made. And Ron, they must love that tech because they shorted by nuance for its amazing balance sheet. No, and it's even closer to 20 billion when you, when you count all the time, you count all the dead, which pales in comparison to, as you said, the 26 billion for LinkedIn, but it's still

a huge deal. And I actually like this deal. Nuance specializes in voice recognition, artificial intelligence. They're actually the company that originally built the back end for Siri back in the day. They're especially strong in health care where they help doctors speed up documentation. They help to predict patients' needs. They improve digital record-keeping at hospitals. This is going to fit perfectly into Microsoft's Cloud for Healthcare Initiative, I believe.

In fact, Microsoft estimated that the combination of both companies should double the total addressable market in the healthcare provider space to nearly $500 billion. So they'll be aggressively attacking that space, I'm sure. These companies have collaborated before. They're no strangers to each other. They have integrated nuances technology into Microsoft Teams in the past. They've had a healthcare collaboration as well. I expect we'll see further collaboration.

collaboration and integration teams, Office 365, perhaps they're even going to go after the automated assistant market to go after Apple and Amazon in that space. Didn't come cheap. These tech acquisitions, companies tend to pay up. Microsoft paid 13 times revenue, 2020 revenue of nuance, which is not as high flying as some of these 30, 40, 50 times sales to revenue, price to revenue we talk about. But still, it's pretty pricey. But overall, I continue to be a really happy shareholder of Microsoft.

I'm a big fan. I think they're executing well. And I think this acquisition makes good sense. By my account, they still have over $100 billion on the balance sheet that they can put to use. Safe to assume we're going to see more acquisitions, maybe not at this level, but they got the money, Ron. They've got the money.

It's a competitive world out there. You know, they're going up against Amazon, Apple in the healthcare space. Even Google has a research effort in healthcare. So I think you'll continue to see acquisitions there as well in other sectors. Not only do they have an unbelievable balance sheet, but they produce gobs and gobs of cash flow each quarter. So, yes, we will continue to see future acquisitions. Another week, another hot new public company. On Wednesday, Coinbase went public through a direct listing.

Coinbase is the most popular crypto exchange in the United States. And now, Emily, it's worth more than $65 billion. Sure. Totally reasonable, right, Chris? I mean, Coinbase has had an incredibly volatile start to its life as a public company. But given the market conditions we're living in today, I can't say that anybody was really surprised. There are lots of good things about the Coinbase platform. They have over $90 billion in crypto assets, which is 11% of the crypto market cap. They have a huge following of institutional users. In fact, nearly 65% of the assets on their platform are owned by institutions.

But there is a really natural level of skepticism that comes into this business, not just based off of its crazy, really immediately high valuation in the public markets, but also just controversies around cryptocurrency in general, how viable it is from a business perspective, as well as the potential for margins to be compressed as competition heats up. I'm glad you mentioned the institutions because one of the things I've heard is that this is a way for, whether it's institutions, hedge fund managers, mutual fund managers, this is a way for them to get exposure to the crypto market without having to essentially pick and choose among the world of Bitcoin.

I mean, is that as much as anything part of the bulk case for something like Coinbase? That it's, I don't want to use the word easy, but I can't think of another one. So is this just an easier entry point for a lot of fund managers? It's an interesting argument because there are a lot of Bitcoin or other cryptocurrency ETFs available. So it's not that Coinbase is the only way to play the market without owning shares of Bitcoin directly. I'll just add. I'm fully aware that we get kind of cynical about some of these things,

these high flyers, these high valuation companies, and we're often wrong in our cynicism. But I'm going to go, I'm going to double down on it anyway, because I fail to understand how this can be valued similarly, if not more than the owner of the New York Stock Exchange, intercontinental exchange, especially understanding that there's going to be lots of competition here. Lots of folks can add on an exchange for cryptocurrencies, and they will not be the only game in town. In fact, they're not the only game in town. But others, if this market continues to be a reasonable opportunity, others are coming for them. And I just, I don't see how that valuation makes any sense. Let me play devil's advocate and try to convince you, Ron,

because there is a good argument that their 0.5% transaction fee, which is their average across, is going to be pulled down as competition heats up. Where I think coin could make up some of that margin increases, is by providing analytics and data services? It is, admittedly, a lot of the things that we see ICE and other exchange providers providing to the people who list on their exchanges. But I do think they can expand more into data and analytics, which can be a higher margin revenue source for them. Well, they better expand quite a bit to grow into that valuation.

Time will tell. It'll be interesting to watch. This week, the Food and Drug Administration asked states to temporarily halt using Johnson and Johnson's COVID-19 vaccine after six people in the U.S. developed a rare blood clotting disorder. The FDA says that this move was out of an abundance of caution. Ron, it's Friday afternoon as we're having this conversation. This is an evolving situation as Johnson and Johnson is in this regulatory limbo. But from a business perspective, at this point, it really doesn't seem like the company's been hurt in any way.

I would tend to agree with that. We'll have to watch how it plays out six people, one death, which obviously is tragic, but out of 6.8 million doses that have gone into arms, I think the phrase abundance of caution is appropriate here because typically I don't think that level of complications would rise to the level of needing to halt something. But we're in unprecedented times here. and kudos to the FDA for being extra cautious here. You know, it's interesting to note that the AstraZeneca vaccine over in Europe had similar issues and came under scrutiny with clotting as well.

Both J&J and AstraZeneca use gene and viral-based technologies, whereas Pfizer and Moderna, which have really had not many issues at all, used a different technology called Messenger RNA, MRNA. RNA. So perhaps there's something there in the way these vaccines are made. J&J in fact asked Pfizer and Moderna to help study blood cloud risks. Interestingly, they declined. AstraZeneca, not surprisingly, he was like, yeah, I'll participate. But Pfizer and Moderna didn't see any reason to go in and duplicate the efforts of regulators. So we'll have to wait to see what happens here. My guess is that J&J will come back on the market. I just hope that this doesn't increase the vaccine hesitancy that we've seen across the world, the U.S.,

not just for health reasons, but it's a business show for economic reasons where we're in the early stages, mid-stages of reopening up. Getting to hurt immunity is an important part of that. Getting vaccines in the arms is an important part. Jay and Jay is very important because it's only one shot and it doesn't require the cold storage of some of the other vaccines. So you can do it in different places of the country, more rural areas for example, it's easier on college campuses, things like that. So, I hope this turns out to be a non-event and J&J comes back on the market relatively soon. Chairs of Stitch Fix down more than 10% this week. After company founder Katrina Lake

announced, she will be stepping down as CEO. She will stay on with the company as executive chair, but Emily, this is kind of surprising when you consider she is only 38 years old. And there are a lot of people out there who bought this stock based on their belief. belief in the CEO? It's certainly a sad day for Stitchfix because Katrina Lake, Stitchfix was her baby. It was her mindchild. She had spent decades, right, developing this idea and this business. And she is relatively young.

But it just goes to show that having a really motivated, invested founder doesn't necessarily mean that the business itself is going to succeed. I like when those two things align. But in this case, I think Stitchfix is kind of fighting an uphill battle with its core. service, which is subscription box clothing. And one area, well, I think Katrina Lake has an amazing job in many areas, one area that I think is right for improvement is this business's strategy. It seems to be confused about if they're using algorithms and AI, if they're using stylists,

or if they're going direct to consumer or subscription boxes. They've been a bit all over to place. So with Elizabeth Spalding coming in as the new CEO, it'll be really interesting to see what strategy she takes in terms of segmenting Stitch Fixes market and really going after one strategy in particular. Coming up, we've got snacks and beverages. If you're looking for something a little stronger, we got that too. Details after the break.

You're listening to Motley Full Money. Chris Hill here with Emily Flippin and Ron Gross. Bedbath and Beyond ended the fiscal year, not with a bang but a whimper. Fourth quarter sales fell double digits. were charges due to store closures and shares of bedbath and beyond down 15% this week. Ron, you and I are both shareholders of this company. I get why the stock is down, but the turnaround that CEO Mark Tritton is trying to pull off is not for the faint of heart.

And I still like what he's doing. Yeah, and I think he's still on track too. Despite the sell-off and the shares this week, you know, the stock had already run up pretty nicely amid the high expectations for Tritton's turnaround and also some of that. that nonsensical Reddit GameStop stuff that they got kind of cut up in. So I think investors were likely to take some money off the table if they saw any weakness in the turnaround story. And in this case, it was the light revenue.

But overall, I think the quarter was solid. Comp sales over across all the stores, up 4%, up 6% across bed bath stores. Third straight quarter of comparable store sales growth. We had the tailwinds from some COVID home-related projects going on, but that was offset by a decline in traffic at the physical stores. As you said, revenue down 16 percent. That's largely due to the divestagers of World Market and Christmas tree shops, which I was actually really pleased to see them get rid of, as well as some planned store closings. So the turnarounds on track. Adjusted gross margin was up a bit less promotional activity going on. Operating expenses

were mostly lower due to the divestitures. So the bottom line looked fine to me. Adjusted EBITDA up 13%. They had earnings per share of 40 cents, which actually beat expectations. They reiterated guidance for fiscal 2021 of around 500 million in EBITDA, which translates to about 8.5 times enterprise value at the current share price, which is not pricey, in my opinion, especially if Triton continues to execute and profitability continues to increase. I happen to be in a bedbath earlier this week, and I will tell you, the re-merchandising is very, very evident. And the focus on private labels such as Nestwell and Haven. There's mostly private label goods in some of the departments there. So, and it was very evident. So let's give Tritton some time.

I think the story is still on track. And despite the pullback, I think we're okay here. Last year, sales of Hard Seltzer were 160 percent higher than the previous year, but one market leader is not sitting still. This week, White Claw introduced Serbs, served. which is hard seltzer with a higher alcohol content, and it comes in a bigger can. Emily, if this is even remotely popular, there is no way Boston Beer Company doesn't do the exact same thing with their truly line of hard seltzer. You know, Chris, I kind of think this is a disaster. And hear me out, hear me out.

White Claw created an entire industry off of convincing alcohol consumers that picking White Claw was the healthier choice. They were small cans, simple design, no carbs or low carbs, only 100 calories, 5% alcohol. I mean, these were the sorts of things that you could sit with your friends out on a patio sipping. If I am at a friend's house, we're having a barbecue and someone pulls out a can of surge, these things are double the calories, double the size, nearly double the alcohol content, you don't think that's going to start a conversation. I mean, It's a Sunday night. What are you doing with your life? I think before we know it, they're going to do the same thing without the carbonation.

And before you know, we're all just drinking whiskey. Here's what I will say, though. And what I think is really critical from an investing standpoint. We saw Constellation brands last week come out with earnings, and they spent a lot of time talking about their Corona Seltzers. They were the second fastest moving Seltzer brand over the last year. So, that's a genuine threat to White Claw. So what I think White Claw was thinking here is, okay, we'll continue with our dominating Seltzer brands, but this new product isn't going to cannibalize any of the people who are already buying White Claws.

It's going to get the four Locos crowd, right? The college students who maybe see a giant can on their way out of total wine and pick it up. I don't know. I don't know. I'm a situation is the sincerest form of flattery. It's not going to surprise me if Boston Bionie. does this with Trulley. We'll stick with beverages. First quarter profits and revenue came

in higher than expected for Pepsi. Ron, as Pepsi waits for restaurants and sporting venues to open at full capacity, the Frito-Lay snack division continues to get it done. As we were all basically sitting home in quarantine snacking, which is the truth, and it's the offset to the fact that restaurants, theater, stadiums were closed and the beverage business was really hurt. So Pepsi has stayed afloat as a lot. the result of their diversified business. Interestingly, just from a stock perspective, shares are up about 6% over the last year, and they're actually down slightly from pre-COVID levels. So, investors not too excited about owning this company right here, right now. Some metrics,

revenues up 6.8%. Free to lay up 4%, Quaker up 2%, and the beverage business up 5%. So numbers look fine. It's just not all that exciting. They're operating expenses, I think, we're pretty well-controlled in the absence of some COVID-related expenses. And you saw a nice increase in margins, which led to a net income or an earnings per share increase of 29 percent as a result of that leverage of margins going up. So that is pretty strong, in my opinion. They reiterated their 2021 guidance, which is mid-single-digit increase in organic revenue, high single-digit increase in earnings per share. And as you said, management predicted an acceleration in growth In the second quarter, as a result of the gradual reopening of restaurants and theaters following

the rollout of vaccines, they said, quote, we've been losing market share in the beverage space in the past. It's getting better. We are gaining share right now. That was interesting to see, because Coca-Cola has kind of been eating their lunch, so to speak, for a bit recently. Interestingly, the company also signaled uncertainty over demand for multi-pack snacks as consumers return to offices and colleges, and we all get out of our living rooms and off of our couches. shares are not too expensive, 23 times, Coke is 25 times, kind of in the same ballpark here. They remain very strong companies. They're just not high growth, high flyers. Well, and we've talked about different businesses pulling forward growth. I saw one industry

report that North American snack sales in 2020 rose 11 percent, and typical growth is more in the range of two to four percent. So it's, I think, I think, I think it's kind of telling that Pepsi's stock really isn't doing all that well when you consider that this division is just going crazy with growth over the pandemic, and it's not likely to continue in 2021. Yeah, and you know, we think of stocks like Disney or the cruises or the airlines as reopening plays here. There's nothing wrong with thinking about Pepsi in the same way.

Once restaurants are back online and theaters and stadiums, that business is going to come back pretty significantly. And if you're only paying 23 times now, you might have some nice upside here. Ron, Emily, we'll see you later in the show. Can I interest you in an industry worth half a trillion dollars? Up next, we'll dig into the business of cosmetics and beauty. Stay right here. This is Motley Full Money. Welcome back to Motley Full Money. I'm Chris Hill. According to some estimates, the cosmetics industry is valued at more than $500 billion. One of the more recent entries into that market is Elf Beauty. And no, Elf Beauty does not sell products for Santa's Little Helpers. Elf stands for eyes, lips, face. Mandy Fields is the chief financial officer at Elf Beauty.

Recently, my colleague Bill Mann, caught up with her to get a sense of where Elf is going in the future and to get an overview of the cosmetics industry. Elf plays in both the color, cosmetics, and skin care space. Both are large industries, both domestically and globally. And we are well positioned to play in both of those spaces. I would start by saying ELF, ELF stands for eyes, lip, space. And so that's usually where I start these conversations. What does ELF even stand for? So, eyes look space. And in the color cosmetics space that we play in, we are what we call on a mass side of color cosmetics. So there's a mass side and there's a prestige side. You think prestige, like you mentioned, L'Oreal, the body of L'Oreal brands largely live in the prestige space,

but they do have the L'Oreal brand that lives in the mass space. And so when you think about some of L'L's key competitors, L'Oreal, Revlon, Cover Girl, Mabelene, those really round out kind of the top five with else being kind of in that fourth or fifth slot there. On the math side, you think about color cosmetics. We are mainly distributed in places like Walmart, Target, ALTA are our top customers. We're also in the drug channel and internationally. And I think one of the key differences with ELF is that we actually were a digitally native brand. So we were founded online back in 2004, and we have that relationship with our consumers.

So direct-to-consumer, and that certainly has played in our favor during COVID, especially, as a lot of consumers have shifted that purchase behavior from in-store to online. So color cosmetics, great category historically has been a growth category. Prior to COVID, it was kind of on a negative-2, negative-3 trend. Patients are, when things open back up, color is going to get back to growth. I want to talk a lot about that over the time that we have together. I do want to make sure when we use industry nomenclature, so maybe give me a definition of what you mean when you say color cosmetics. Like what is that exactly? Sure. Color cosmetics.

So just think about lipstick. Like I said, eyes, lip space. So anything you put on your eyes, lip space, eye shadow, mascara, blush, foundations, concealers, primers, all of those things fall under color cosmetics. And then, like I said, we also have our skincare side, which has been a growth driver for us as well. And skincare cleansers, moisturizers, things of that nature. So skin care, so just to define them, skin care is probably something that you're not looking

at to, like, change the shading of what you are, you know, of your face. That is actual, actual, actual care. So, okay, fantastic. And so you've given us a little bit of where ELF fits into the industry. But you mentioned both prestige and mass. Mass. Yes. What is the difference between the two? Or is there a bright line between them in terms of how an ELF would interact with it?

10 customers versus a prestige brand? Actually, now there's a new term called Mass Steed out there. That is really the blend of both Mass and Prestige. Of course there is. And so I guess the way to think about it is, like I said, math players traditionally are kind of those Walmart targets, the drug channel of the world. And then you have Ulta's of the world.

We really start to play in what we call Mass Steed space and then into Prestige. And I think the great thing about Else is that Elf beauty has really been on an evolution over the last year, from moving from single brand in the mass space to now we have three brands under our portfolio. We have Else, which is kind of more on the value side of things in the mass space. We have Well People, which is kind of more so in the middle from a price point standpoint, but also distributed in Target and has presence in Ulta. as well. And then we have our key sole care brand that we just launched in December that really

sits on the kind of more in that prestige space. And you talk about kind of where it's distributed, kind of exclusive with ALTA, and with price points kind of in that $20 to $40 range is more so on the prestige side of thing. It had to be particularly going back a year ago from now. And you started in 2019. Late in the year. It was spring of 2019. Okay, so you were about a year in and suddenly, suddenly everything's shutting down for a brand that's about beauty, that's about self-care. You had to be really careful that you weren't doing something, that you weren't missing the boat on what people were feeling at that moment. That's right.

In March of 2020, not that many people were worried about feeling beautiful. Yeah, no, and there's no doubt about it. I mean, March of 2020, you know, we saw significant declines in the business. And, you know, we went into kind of COVID contingency mode. Like, what are the plans that you're putting in place to weather this storm? And, you know, the first thing I did, having been in a highly levered environment prior to ELF, I went out and made sure our credit agreement was amended. So our covenants, you know, remain intact during this time. But outside of that, our first priority was really making sure our consumers and our employees were safe.

And so we did not fall tone deaf to that at all. We did not continue with our marketing campaign that we had been on prior to that. We flipped, and you mentioned, Eyeslip Safe was one of the things, Eyeswip Space Safe was one of the things that we did to really educate people. Wash your hands. you know, make sure you use the sanitizer. We started sending out hand sanitizer with every purchase on elsepothesmedics.com. We sent care packages to our employees making sure they had masks and gloves and bleach wipes and whatever it is that they needed in those early days. So we wanted to make

sure that everybody felt safe. We made donations during that time to food banks because we knew people were in need during that time. And so we really, you know, are a company that care. about our consumers, our employees, and making sure everybody felt connected. You talked about interviewing the CPO from Zoom. I mean, we have leveraged Zoom so much. There's so much communication now during this time. And so big credit to Zoom for keeping us all together. Could you just imagine if this had happened even five years before?

Oh, my gosh. I know. Really? Yeah. We would have done. We would have been out of school for a year. They would have had to have sent a pigeon to tell me that things were opening back up. Yeah, exactly.

Just, yeah. No, it really, it really has been remarkable. So I'm going to ask a question. I'm going to try not to sound like an idiot in doing so. So it's totally okay for you to say, that's really not a great question. My first, as an analyst, the first company that I ever analyzed in your, in your industry. It's a company called Amori Pacific, and they're based in Korea. And this was 10 years ago, and they had made the point very strongly that most cosmetics

companies did not have a palette that was reflective of their market. Their market was primarily Korea, Japan, China. How much is the industry changed now? How much is the industry change so that the palates meet everyone where they want to be. Yeah. Did I do okay with the question? You did okay with a question. Yes. What you're getting at is the diversity, making sure people feel represented in

color cosmetics. And I think that the industry has made a lot of strides in the right direction, especially else. We certainly have making sure that we have, you know, concealers and foundations that kind of represent the full shade range, certainly more room for us to continue to improve upon that and, you know, make additional shades, making sure people feel well represented in everything. I will say that from a diversity standpoint, it does start at the top. And so our board is, you know, starting with our board, very diverse. Over 55% women, 20% black representation,

on our board, which is very rare. I think our diversity stats put us in like one of three publicly traded companies with that kind of profile. Our executive team is also quite diverse. You don't normally see that in these types of companies, publicly traded large companies. And then our employee population, you know, over 75% women, very much at least towards millennial. I think it's over 60% millennial and over 30%, 35% diverse. So we have started to really see that at the top and that it filters down to all of our decision-making when it comes to colors and talents, our shade ranges, how we show up in our marketing, making sure that from a marketing standpoint, when we put images on Instagram and out there in social media, that is fully representative

of everyone out there. So I'm going to close with this. So my wife is a professional who's also been working home for a lot of the year. And last week I went downstairs and she was wearing heels and she'd had earrings on. It was a little shocking to me. And it wasn't shy. She looked amazing, but it was a little shocking because it's the kind of thing that we used to do all the time.

We always were about, you know, dressing up a little, trying to feel attractive. 2020 and the beginning of 2021, changed that a lot for a lot of people. Yeah. And you all shifted very well. Your numbers reflected. I feel and hope like we're about to shift again. Yeah.

What do you feel like? What is ELF's strategy or thoughts to as we all come out of our cocoon? What is 2022 and 2023 going to look like for you? Yeah. Well, as you said, Elf has done well during, we were doing well before the pandemic, have done well during and feel well positioned as we come out of the pandemic. And we have continued to build share over that time and feel good about our ability to continue to build market share.

As we look forward, you know, we're hopeful that things are opening back up and vaccines roll out and people get back to wanting to get out there. We've heard people call it the roaring 20. will come back and people will want to really get out there. Seems a little aspirational so far. Yeah, I know. And so we're cautiously, you know, consciously monitoring the situation. You know, it will be, I think, a full recovery, totally dependent on the speed, a vaccination rollout, and how quickly people can get back to, you know, what they were doing prior to the pandemic. That's right. And so we're watching it and we're hopeful.

Up next, Ron Gross and Emily Flip and Return with a couple of of stocks on their radar. Stay right here. You're listening to Motley Fool Money. As always, people on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against. So, don't buy or sell stocks based solely on what you hear. Welcome back to Motley Fool Money. Chris Hill here once again with Emily Flippen and Ron Gross. Last fall, IBM announced it was spinning off one-fourth of its business to focus on opportunities in hybrid cloud growth. At the time, IBM used the word NuCo as a temporary placeholder name for the business.

This week, IBM announced the permanent name of the new company is Kindrel, K-Y-N-D-R-Y-L. The company said, and I'm quoting here, Kindrel is a modern adaptation of two words that are central to the new company's identity and mission. Kin is derived from the word kinship, referencing the belief that relationships with people are at the center of the strategy, and that long-lasting relationships must be built and nurtured. Drill comes from tendril, bringing to mind new growth and the idea that business is always working toward advancing human progress. Emily, where would you like to start? I genuinely don't know where to begin. I imagine there's somebody out there, really patting

themselves on their back for writing this up, feeling really proud. And it's, It's hilarious, not just because kinship and tendril, they replace the eyes with wise. So that just adds an extra level to unpack here. But it's the fact that IBM is doing it. The more I think about this, and I've had a couple of hours to ponder over this name change this morning. So I've developed a rather sophisticated take, if you don't mind me saying. It's IBM, international business machines, the world's oldest most legacy name, now going a complete 180, too far to the other end. Kindrel. This is a naming disaster, Chris.

Well, I would agree, and I know we tend to make fun of these new names on the show, Mondalese. We got a lot of laughter out of as well as a number truist. But you can do it right. Like, I think Accenture is fine. Accent on the Future. It makes perfect sense to me. And it's not that hard to pronounce or spell. So you can get this done if you really want go that route. However, this is, I think, a big miss. I'm glad you mentioned Truis, Ron, because one of my thoughts was, the people who came up with Truis must be high-fiving each other right now. They must feel so good about themselves relative to Kendrell. Let's get to the stocks on our radar. Our man behind the glass

Dan Boyd is going to hit you with a question. Emily, flipping, you're up first. What are you looking at this week? I am looking at Beely Beely. The ticker is B-I-L-I. It is a Chinese live-streaming service that's back on my radar after listening to some great thoughts from Aaron Bush and his team over at Master the Medal last week. Beely Pelea-Peeley has really reinvented its business to become diversified not just live streaming, not just gaming, but e-commerce and social interaction platform. It's truly taking up a lot of market share in China, and it's one that I'm really excited to be a shareholder of. Dan, question about Beely Beely. Sure thing, Chris. Emily, over the last three months, four months here since January, the stock has

been on a little bit of a wild ride. What do you think for the next eight months? Is this volatility going to calm down at all? Bele-Billy is volatile, not just because it's a Chinese company, but it also had a little bit of controversy earlier this year regarding some content that they had featured on their site taken from Japan that was, to be kind, less than appropriate. I will expect this business to continue to be volatile, especially since they're going through a business transformation, but I do think Beely-Beeley long-term could be $100 billion plus business. Ron Gross, what's on your radar this week? Dan, because I know you're a huge fan of specialty chemical companies and you're a huge fan

of making fun of me. I'm going to go with EcoLab, ECL, leading provider of cleaning, sanitation, other specialty chemical products and services, $12 billion in sales, global leader in water, hygiene, infection, prevention solutions, low risk profile, long track record of success, gaining share from rivals, margins have been improving. They're increasing innovation through growth investments, moving into digital technologies and sale capabilities. They've raised their dividend annually for the past 29 years, and they've paid dividends for 84 consecutive years. Yield is just under 1%. So, not huge, but hey, it'll beat cash every day. And I think you'll have a nice total

return opportunity with both the yield and price appreciation going forward. Dan, question about EcoLab? You know, I was just thinking, what does the value of a stock make a value investor, or does a value investor search for value stocks? This is a classic Wheelhouse Ron stock. It's chemicals. It's a dividend aristocrat. It's been around for almost 100 years. What run, is it you? Or is it the stocks when you are pitching me on these value stocks? It's the pond efficient, right? I think so. I don't necessarily understand technology as well as some, and I can't predict the future as well as some. So I gravitate to these more old economy companies that for me are easier to predict and to value.

What do you want to add to your watch list, Dan? Well, I like giving Ron a little bit of, you know, ribbing every now and then about his stocks, but I actually like Eco Lab a whole lot. I think there is a lot of future in water and how important that's going to be to a lot of people. So, I'm going to go with Eco Lab. What do I do? What do I need to do to get you on my side, Dan? I don't know. I mean, water or Chinese video games? It's clear to me. It's clear to me. So is water.

We're out of time. Emily Flipping, Ryan Gross. Thanks for being here. Thanks, Chris. That's going to do it for this week's show. Our producers, Matt Creer. The show is Mixed by Dan Boyd. I'm Chris Hill. We'll see you next week.